Could Lannett Company, Inc. (LCI) Recover After Today’s Huge Decline?

Investors sentiment increased to 1.67 in 2019 Q1. Its up 0.80, from 0.87 in 2018Q4. It is positive, as 9 investors sold Lannett Company, Inc. shares while 36 reduced holdings. 25 funds opened positions while 50 raised stakes. 39.26 million shares or 26.71% more from 30.98 million shares in 2018Q4 were reported.
Martingale Asset Mgmt L P stated it has 0.01% in Lannett Company, Inc. (NYSE:LCI). Rafferty Asset Mgmt Limited Liability Corp owns 344,463 shares. Wells Fargo And Mn invested in 113,467 shares. The New York-based Blackrock Inc has invested 0% in Lannett Company, Inc. (NYSE:LCI). Susquehanna Limited Liability Partnership has invested 0% of its portfolio in Lannett Company, Inc. (NYSE:LCI). The Maryland-based Adams Diversified Equity Fund Inc has invested 0.01% in Lannett Company, Inc. (NYSE:LCI). Spark Inv Mngmt Limited Liability, a New York-based fund reported 505,058 shares. Optimum Invest Advisors holds 5,000 shares. Meeder Asset Mngmt holds 0% of its portfolio in Lannett Company, Inc. (NYSE:LCI) for 1,673 shares. Citadel Lc holds 676,846 shares. Vanguard reported 2.01M shares. Natl Bank Of Ny Mellon Corporation holds 1.22 million shares. Texas Permanent School Fund stated it has 0% of its portfolio in Lannett Company, Inc. (NYSE:LCI). Dimensional Fund Advsr Limited Partnership holds 800,871 shares. Gabelli Funds Ltd Liability Company stated it has 0% of its portfolio in Lannett Company, Inc. (NYSE:LCI).

Since March 31, 2019, it had 2 insider buys, and 0 selling transactions for $49,550 activity. Crew Timothy C also bought $20,550 worth of Lannett Company, Inc. (NYSE:LCI) shares.

The stock of Lannett Company, Inc. (NYSE:LCI) is a huge mover today! The stock decreased 4.73% or $0.32 during the last trading session, reaching $6.45. About 509,729 shares traded. Lannett Company, Inc. (NYSE:LCI) has declined 42.05% since August 14, 2018 and is downtrending. It has underperformed by 42.05% the S&P500.
The move comes after 9 months negative chart setup for the $253.64 million company. It was reported on Aug, 14 by Barchart.com. We have $6.00 PT which if reached, will make NYSE:LCI worth $17.75M less.

Analysts await Lannett Company, Inc. (NYSE:LCI) to report earnings on August, 27. They expect $0.21 EPS, down 67.19 % or $0.43 from last year’s $0.64 per share. LCI’s profit will be $8.26M for 7.68 P/E if the $0.21 EPS becomes a reality. After $0.68 actual EPS reported by Lannett Company, Inc. for the previous quarter, Wall Street now forecasts -69.12 % negative EPS growth.

More notable recent Lannett Company, Inc. (NYSE:LCI) news were published by: Digitaljournal.com which released: “SHAREHOLDER ALERT: Shareholder Class Action Against Lannett Company (LCI) Survives Motion to Dismiss; The Law Offices of Timothy L. Miles Encourages Shareholders to Contact the Firm – Press Release – Digital Journal” on July 19, 2019, also Seekingalpha.com with their article: “LCI Industries: Free Falling RV Segment Could Sting – Seeking Alpha” published on July 24, 2019, Benzinga.com published: “Option Trader Makes Bullish Bet On Lannett Rebound – Benzinga” on July 16, 2019. More interesting news about Lannett Company, Inc. (NYSE:LCI) were released by: Seekingalpha.com and their article: “Lannett OKs Cody Labs restructuring plan – Seeking Alpha” published on June 17, 2019 as well as Streetinsider.com‘s news article titled: “‘Notable’ Call Buying Activity Continues in Lannett (LCI) with Shares Up Over 35% on the Session – Susquehanna – StreetInsider.com” with publication date: July 22, 2019.

Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. The company has market cap of $253.64 million. The firm offers solid oral, extended release, topical, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, patch, foam, buccal, sublingual, soft gel, and injectable dosages. It currently has negative earnings. It also provides its products for various medical indications comprising glaucoma, cholesterol, muscle spasm, migraine, pain management, cardiovascular, antipsychosis, gastrointestinal, urinary, bronchospasms, respiratory, gallstone, congestive heart failure, thyroid deficiency, central nervous system, and gout.

Lannett Company, Inc. (NYSE:LCI) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.